Braidwell’s Maravai LifeSciences MRVI Stock Holding History

Braidwell’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$54.3M	Sell	8,702,921 -1,537,243	-15%	-$6.64M	2.01%	16
2026 Q1	$29M	Buy	10,240,164 +1,886,877	+23%	+$6.4M	0.97%	38
2025 Q4	$27.1M	Hold	8,353,287	–	–	0.87%	45
2025 Q3	$24M	Hold	8,353,287	–	–	0.71%	41
2025 Q2	$20.1M	Hold	8,353,287	–	–	0.69%	37
2025 Q1	$18.5M	Hold	8,353,287	–	–	0.65%	42
2024 Q4	$45.5M	Hold	8,353,287	–	–	1.35%	29
2024 Q3	$69.4M	Sell	8,353,287 -670,750	-7%	-$5.8M	1.97%	21
2024 Q2	$64.6M	Buy	9,024,037 +1,802,077	+25%	+$15.6M	2.03%	18
2024 Q1	$62.6M	Buy	7,221,960 +2,181,325	+43%	+$14.8M	2.02%	16
2023 Q4	$33M	Buy	5,040,635 +1,065,778	+27%	+$6.89M	1.21%	33
2023 Q3	$39.7M	Buy	3,974,857 +2,170,157	+120%	+$23.8M	1.26%	30
2023 Q2	$22.4M	Buy	+1,804,700	New	+$24.4M	0.73%	50

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Braidwell's MRVI Position: Q2 2026 in Review

Braidwell reduced its Maravai LifeSciences (MRVI) stake by 15% in Q2 2026, selling an estimated $6.64M and leaving 8,702,921 shares worth $54.3M. The position accounts for 2.01% of the portfolio, ranked #16.

Braidwell first reported a position in MRVI in Q2 2023 and has held it in 13 quarters since. The position peaked at $69.4M in Q3 2024. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

Braidwell held 8,702,921 shares of Maravai LifeSciences worth $54.3M as of Q2 2026.
Braidwell sold 1,537,243 Maravai LifeSciences shares in Q2 2026, an estimated $6.64M.
Maravai LifeSciences made up 2.01% of Braidwell's portfolio in Q2 2026, its #16 holding.
Braidwell first reported a position in Maravai LifeSciences in Q2 2023 and has held it in 13 quarters since.
Braidwell's Maravai LifeSciences position peaked at $69.4M in Q3 2024.
178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.